EP0994848A1 - Antagonistes/agonistes inverses du glucagon - Google Patents

Antagonistes/agonistes inverses du glucagon

Info

Publication number
EP0994848A1
EP0994848A1 EP98929244A EP98929244A EP0994848A1 EP 0994848 A1 EP0994848 A1 EP 0994848A1 EP 98929244 A EP98929244 A EP 98929244A EP 98929244 A EP98929244 A EP 98929244A EP 0994848 A1 EP0994848 A1 EP 0994848A1
Authority
EP
European Patent Office
Prior art keywords
lower alkyl
γçö
aryl
hydrogen
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98929244A
Other languages
German (de)
English (en)
Inventor
Javier Gonzales
Christian Sams
Min Teng
Anthony Ling
Vlad Gregor
Yufeng Hong
Dan Kiel
Atsuo Kuki
Shenghua Shi
Lars Naerum
Peter Madsen
Jesper Lau
Michael Bruno Plewe
Jun Feng
Michael David Johnson
Kimberly Ann Teston
Ulla Grove Sidelmann
Lotte Bjerre Knudsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Agouron Pharmaceuticals LLC
Original Assignee
Novo Nordisk AS
Agouron Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS, Agouron Pharmaceuticals LLC filed Critical Novo Nordisk AS
Publication of EP0994848A1 publication Critical patent/EP0994848A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/45—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms doubly-bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the present invention relates to agents that act to antagonize the action of the giucagon peptide hormone. It relates particularly to non-peptide giucagon antagonists or inverse agonists.
  • giucagon can be suppressed by providing an antagonist or an inverse agonist, substances that inhibit or prevent giucagon induced response.
  • the antagonist can be peptide or non-peptide in nature.
  • Native giucagon is a 29 amino acid- containing peptide having the sequence: His-Ser-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp- Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-NH 2 .
  • Giucagon exerts its action by binding to and activating its receptor, which is part of the Glu- cagon-Secretin branch of the 7-transmembrane G-protein coupled receptor family (Jelinek et al. Science 259, 1614, (1993)).
  • the receptor functions by activation of the adenylyl cyclase second messenger system and the result is an increase in cA P levels.
  • WO 94/14426 discloses use of skyrin, a natural product comprising a pair of linked 9,10-anthracenedione groups, and its synthetic analogues, as giucagon antagonists.
  • Anderson, P.L., U.S. Patent No. 4,359,474 discloses the giucagon antagonistic properties of 1- phenyl pyrazole derivatives.
  • Barcza, S., U.S. Patent No. 4,374,130 discloses substituted disi- lacyclohexanes as giucagon antagonists.
  • WO 98/04528 (Bayer Corporation) discloses substituted pyridines and biphenyls as giucagon antagonists.
  • WO 97/16442 discloses substituted pyridyl pyrroles as giucagon antagonists
  • WO 98/21957 discloses 2,4-diaryl-5-pyridylimidazoles as giucagon antagonists. These giucagon antagonists differ structurally from the present compounds. Description of the invention
  • Halogen designates an atom selected from the group consisting of F, Cl, Br or I.
  • alkyl in the present context designates a hydrocarbon chain or a ring that is either saturated or unsaturated (containing one or more double or triple bonds where feasible) of from 1 to 10 carbon atoms in either a linear or branched or cyclic configuration.
  • alkyl includes for example n-octyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, allyl, propargyl, 2- hexynyl, cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclohexyl, cyclooctyl, 4-cyclohexylbutyl, and the like.
  • non-limiting examples are sec-butyl, n-pentyl, isopentyl, neopentyl, te/ ⁇ -pentyl, n- hexyl, isohexyl, n-heptyl, n-nonyl, n-decyl, vinyl, 1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-1-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 3-met.hyl-2-but.enyl, 1- hexenyl, 3-hexenyl, 2,4-hexadienyl, 5-hexenyl, 1-heptenyl, 2,4-heptadienyl, 1-octenyl, 2,4- octadienyi, ethynyl, 1-propynyl, 1-butynyl, 2-butyn
  • lower alkyl designates a hydrocarbon moiety specified above, of from 1 to 6 carbon atoms.
  • Aryl means an aromatic ring moiety, for example: phenyl, naphthyl, furyl, thienyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazolyl, imidazolyl, pyrazinyl, pyridazinyl, 1 ,2,3-triazinyl, 1 ,2,4-triazinyl, oxazolyl, isoxazolyl, 1 ,2,3-oxadiazolyl, 1 ,2,4-oxadiazolyl, 1 ,3,4-oxadiazolyl, 1 ,2,3-thiadiazolyl, 1 ,2,4-thiadiazolyl, 1 ,3,4-thiadiazolyl, thiazolyl, isothiazolyl, tetrazolyl, 1-H-tetrazol-5-yl, indolyl, quinolyl, quinazolinyl, benzofuryl, be
  • the aryl moieties are optionally substituted by one or more substituents, for example selected from the group consisting of F, Cl, I, and Br; lower alkyl; lower alkanoyl such as formyl, acetyl, propionyl, butyryl, valeryl, hexanoyl and the like; -OH; -NO 2 ; -CN; -CO 2 H; -O-lower alkyl; aryl; aryl-lower alkyl; -CO 2 CH 3 ; -CONH 2 ; -OCH 2 CONH 2 ; -NH 2 ; -N(CH 3 ) 2 ; -SO 2 NH 2 ; -OCHF 2 ; -CF 3 ; -OCF 3 and the like.
  • Such aryl moieties may also be substituted by two substituents forming a bridge, for example -OCH 2 O-.
  • the aryl group is optionally substituted as described above.
  • the present invention is based on the unexpected observation that compounds having a selected nitrogen-bearing central motif and the general structural features disclosed below antagonize the action of giucagon. Accordingly, the invention is concerned with compounds of the general formula
  • R 1 and R 2 independently are hydrogen or lower alkyl or together form a valence bond
  • n 0, 1, 2 or 3;
  • n 0 or 1 ;
  • R 5 is hydrogen, lower alkyl, aryl-lower alkyl or -OR 6 ;
  • R 6 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 7 is hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 11 , -NR 11 R 12 , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SO 2 NR 11 R 12 , -SR 11 , -CHF 2 , -OCHF 2 , -OSO 2 R 11 , -CONR 11 R 12 , -OCH 2 CONR 11 R 12 , -CH 2 OR 11 , -CH 2 NR 11 R 12 , -OCOR 11 , -CO 2 R 13 or -OSO 2 CF 3 ;
  • R 8 and R 9 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 11 , -NR 11 R 12 , lower alkyl, aryl, -SCF 3 , -SR 11 , -CHF 2 , -OCHF 2 , -OSO 2 R 11 , -CONR 11 R 12 , -CH 2 OR 11 , -CH 2 NR 11 R 12 , -OCOR 11 , -CO 2 R 13 or -OSO 2 CF 3 , or R 8 and R 9 together form a bridge -OCH 2 O- or -OCH 2 CH 2 O-;
  • R 11 and R 12 independently are hydrogen, -COR 13 , -SO 2 R 13 , lower alkyl or aryl;
  • R 10 is hydrogen, lower alkyl, aryl-lower alkyl or aryl;
  • R 14 and R 15 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3> -O(CH 2 ) ! CF 3 , -NO 2 , -OR 16 , -NR 16 R 17 , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SR 16 , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2 , -OSO 2 CF 3 , -CONR 16 R 17 , -(CH 2 ),CONR 16 R 17 , -O(CH 2 ),CONR 16 R 17 , -(CH 2 ),COR 16 , -(CH 2 ),COR 16 , -(CH 2 ),COR 16 , -(CH 2 ),OR 16 , -O(CH 2 ),OR 16 , -(CH 2 ),NR 16 R 17 , -O(CH 2 ),NR 16 R 17 ,
  • I is 1 , 2, 3 or 4;
  • R 16 and R 17 independently are hydrogen, -COR 18 , -SO 2 R 18 , lower alkyl, aryl, or R 16 and R 17 together form a cyclic alkyl bridge containing from 2 to 7 carbon atoms;
  • R 18 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 19 , R 20 , R 21 and R 22 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 24 , -NR 24 R 25 , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SR 24 , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2 , -OSO 2 CF 3 , -CONR 24 R 25 , -CH 2 CONR 24 R 25 , -OCH 2 CONR 24 R 25 , -CH 2 OR 24 , -CH 2 NR 4 R 25 , -OCOR 24 or -CO 2 R 24 , or R 19 and R 20 , R 20 and R 21 , or R 21 and R 22 together form a bridge -OCH 2 O-; wherein R 24 and R 25 independently are hydrogen, -COR 26 , -SO
  • R 26 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 23 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 3a , R 3b , R 4a and R 4b independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 24a , -NR 24a R 25a , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SR 24a , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2, -OSO 2 CF 3 , -CONR 24a R 25a , -CH 2 CONR 24a R 25a , -OCH 2 CONR 24a R 5a , -CH 2 OR 24a , -CH 2 NR 24a R 25a , -OCOR 24a or -CO 2 R 24a ;
  • R 24a and R 25a independently are hydrogen, -COR 26a , -SO 2 R 26a , lower alkyl, aryl or aryl-lower alkyl;
  • R 26a is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 3a and R 3b , R 4a and R 4b , or R 3a and R 4b together form a bridge -(CH 2 ) r ;
  • i is 1 , 2, 3 or 4;
  • a, b, c and d independently are 0, 1 , 2, 3 or 4; e, f and p independently are 0 or 1 ;
  • q 0, 1 or 2;
  • k is 1 , 2, 3 or 4;
  • R 6a and R 6b independently are hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 43 is hydrogen or lower alkyl
  • G" is -OCH 2 CO-, -CH 2 CO-, -CO- or a valence bond
  • F' is >CR 38 - or >N-;
  • Q' is -NR 36 -, -O- or -S-;
  • R 27 and R 28 , R 32 and R 33 , R 33 and R 34 , or R 34 and R 35 together form a bridge -O(CH 2 ) y O-;
  • y is 0, 1 , 2, 3 or 4;
  • R 29 and R 30 independently are hydrogen, -COR 31 , -CO 2 R 31 , -SO 2 R 31 , lower alkyl, aryl or aryl-lower alkyl; wherein R 31 is hydrogen, lower alkyl, aryl or aryl-lower alkyl;
  • R 36 and R 39 independently are hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • x is 1 , 2, 3 or 4;
  • R 40 and R 41 independently are hydrogen, -COR 42 , -SO 2 R 42 , lower alkyl, aryl or aryl-lower alkyl;
  • R 19 , R 20 , R 21 , R 22 and R 23 may alternatively be re- placed by R 14 or R 1S , respectively.
  • R 32 , R 33 , R 34 , R 35 , R 36 , R 38 and R 39 may alternatively be replaced by R 27 or R 28 , respectively.
  • A is more preferably
  • R 8 and R 9 are independently selected from hydrogen, halogen such as -F and -Cl, -O-lower alkyl such as methoxy and ethoxy, -NH 2 , -CNor -NO 2 , and R 10 is hydrogen.
  • R 8 and R 9 independently are hydrogen, halogen, -OH, -NO 2 , -NH 2 , -CN, -OCF 3 , -SCF 3 , -CF 3 , -OCH 2 CF 3 , -O-lower alkyl such as methoxy and ethoxy, lower alkyl such as methyl and ethyl, or phenyl, preferably hydrogen, halogen such as -F and -Cl, -O-lower alkyl such as methoxy and ethoxy, -NH 2 , -CNor -NO 2 .
  • R 8 is hydrogen, halogen such as -F or -Cl, -O-lower alkyl such as -OCH 3 or -OC 2 H 5 , -NH 2 , -CN or -NO 2 ; and R 9 is hydrogen or halogen such as -F or -Cl.
  • R 8 is halogen and R 9 is hydrogen.
  • Q is preferably -O- or -NH-.
  • R 14 and R 15 independently are hydrogen, halogen, -CF 3, -OCF 3 , -OR 16 , -NR 16 R 17 , lower alkyl, aryl, aryl-lower alkyl, -OS0 2 CF 3 , -CONR 16 R 17 , -CH 2 OR 16 , -CH 2 NR 6 R 17 , -OCOR 16 or -CO 2 R 18 ; or R 14 and R 15 together form a bridge -OCH 2 O- or -(CH 2 ) r ;
  • R 14 and R 15 independently are hydrogen, halogen, -CF 3, -OCF 3 , -OR 16 , -NR 16 R 17 , lower alkyl, aryl, aryl-lower alkyl, -OSO 2 CF 3 , -CONR 16 R 17 , -CH 2 OR 16 , -CH 2 NR 16 R 17 , -OCOR 16 or -CO 2 R 18 ; or R 14 and R 15 together form a bridge -OCH 2 O- or -(CH 2 ) r ;
  • I, R 6 , R 17 and R 18 are as defined for formula I; K, D and m are as defined for formula I; and
  • R 8 and R 9 are as defined for formula I and preferably as defined for the preferred embodiments of A above.
  • R 14 and R 15 are preferably independently hydrogen, halogen, lower alkyl, aryl such as phenyl, or -O-lower alkyl such as methoxy.
  • K is preferably bound in para-position and in the above formulae Villa and Vlllb, K is preferably bound at the nitrogen atom of the indole group.
  • K is preferably selected from the group consisting of:
  • R 3a , R 3 , R 4a , R 4b , R 5a , R 5b , a, b, c, d, p and q are as defined for formula I.
  • K is selected from the group consisting of:
  • R 3a , R 3b , R 4a , R 4b , R 5a , R 5b , a, b, c, d, p and q are as defined for formula I.
  • R 3a , R 3b , R 4a , R 4b , R 5a , R 5b , b, c, d, p and q are as defined for formula I.
  • g and k are independently 1 , 2 or 3
  • R 6a and R 6b are independently hydrogen, lower alkyl such as methyl or ethyl, or aryl such as phenyl,
  • R 3a and R 3b are preferably independently hydrogen, halogen, -OH, -O-iower alkyl, -COO-lower alkyl, lower alkyl or aryl-lower alkyl.
  • R a and R b are preferably independently hydrogen, -CN, -CONH 2 , -(CH 2 )-N(CH 3 ) 2 , -O-lower alkyl, -CH 2 OH, -CH 2 O-aryl, -N(CH 3 ) 2 , -OH, -CO 2 -lower alkyl or lower alkyl.
  • D is preferably hydrogen
  • D is hydrogen
  • D is more preferably hydrogen
  • R 3 and R 4 independently are hydrogen or lower alkyl
  • n 0, 1 , 2 or 3;
  • n 0 or 1 ;
  • R 5 is hydrogen, lower alkyl, aryl-lower alkyl, or -OR 6 ;
  • R 6 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 7 is hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 11 , -NR 11 R 12 , lower alkyl, aryl, -SCF 3 , -SR 11 , -CHF 2 , -OCHF 2 , -OSO 2 R 11 , -CONR 11 R 12 , -CH 2 OR 11 , -CH 2 NR 1 R 12 , -OCOR 11 , -CO 2 R 13 , -OSO 2 CF 3 .
  • R 8 and R 9 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 11 , -NR 11 R 12 , lower alkyl, aryl, -SCF 3 , -SR 11 , -CHF 2 , -OCHF 2 , -OSO 2 R 11 , -CONR 11 R 12 , -CH 2 OR 11 , -CH 2 NR 1 R 12 , -OCOR 11 , -CO 2 R 13 , -OSO 2 CF 3 , or R 8 and R 9 together form a bridge -OCH 2 O-;
  • R 1 and R 12 independently are hydrogen, -COR 13 , -SO 2 R 13 , lower alkyl or aryl;
  • R 13 is hydrogen, lower alkyl, aryl-lower alkyl or aryl;
  • R 10 is hydrogen, lower alkyl, aryl-lower alkyl or aryl;
  • R 14 and R 15 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -O(CH 2 )
  • R 14 and R 5 preferably independently representing hydrogen, halogen, -CF 3, -OCF 3 , -OR 16 , -NR 16 R 17 , lower alkyl, aryl, aryl-lower alkyl, -OSO 2 CF 3 , -CONR 16 R 17 , -CH 2 OR 16 , -CH 2 NR 16 R 17 , -OCOR 16 or -CO 2 R 18 ; or together forming a bridge -OCH 2 O-;
  • I is 1 , 2, 3 or 4;
  • R 16 and R 17 independently are hydrogen, -COR 18 , -SO 2 R 18 , lower alkyl, aryl, or R 16 and R 17 together form a cyclic alkyl bridge containing from 2 to 7 carbon atoms;
  • R 18 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 19 , R 20 , R 2 and R 22 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 24 , -NR 24 R 25 , lower alkyl, aryl, aryl-lower alkyl, SCF 3 , -SR 24 , -CHF 2 , -OCHF 2 , OCF 2 CHF 2 , -OSO 2 CF 3 , -CONR 24 R 25 , -CH 2 CONR 24 R 25 , -OCH 2 CONR 24 R 2 VCH 2 OR 24 , - CH 2 NR 24 R 25 , -OCOR 24 or -CO 2 R 24 , or R 19 and R 20 , R 20 and R 21 or R 21 and R 22 together form a bridge -OCH 2 O-;
  • R 24 and R 25 independently are hydrogen, -COR 26 , -SO 2 R 26 , lower alkyl, aryl or aryl-lower alkyl;
  • R 26 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 23 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 3a , R 3b , R 4a and R 4b independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 24a , -NR 24a R 25a , lower alkyl, aryl, aryl-lower alkyl, SCF 3 , -SR 24a , -CHF 2 2 ,, -O v_/Cv_#H ⁇ ⁇ F 22 ,, -CONR 24a R 25a , -CH 2 CONR 24a R 25a , -OCH 22 CCOONNRR 44aa RR 2255aa ,, --CCHH 22 OORR 2244aa ,, --CCHH 22 IN,R ⁇ 24a ,R ⁇ 25a ,, --OCO.RX 24a U o,r -- W CO 22 .RX 24a - , wherein R 2 a and R 25a independently are hydrogen
  • R 26a is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 3a and R 3b , R 4a and R 4b or R 3a and R 4b together form a bridge -(CH 2 ) r , wherein
  • i 1 , 2, 3 or 4;
  • a, b, c and d independently are 0, 1 , 2, 3 or 4;
  • e, f, p and q independently are 0 or 1 ;
  • R 5a and R 5b independently are hydrogen, lower alkyl, -(CH 2 ) k -OH, -(CH 2 ) k - NR 6a R 6b , aryl or aryl-lower alkyl;
  • k is 2, 3 or 4;
  • R 6a and R 6b independently are hydrogen, lower alkyl or aryl-lower alkyl
  • K preferably representing — (CH 2 ) b -0— (CH 2 ) d , (CH2 j_ CH - CH _ (CH2)d
  • Q' is -NR 36 -, -O- or -S-;
  • R 27 , R 28 , R 32 , R 33 , R 34 and R 35 are independently hydrogen, halogen, -CN, -CF 3 , -OCF 3> _O(CH 2 ) y CF 3 , -NO 2 , -OR 29 , -NR 29 R 30 , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SR 29 , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2> -OSO 2 R 29 , -OSO 2 CF 3 , -CONR 29 R 30 , -(CH 2 ) y CONR 29 R 30 , -O(CH 2 ) y CONR 29 R 30 , -(CH 2 ) y OR 29 , -(CH 2 ) y NR 29 R 30 , -OCOR 29 , -CO 2 R 29; or R 27 and R 28 , R 32 and R 33 ,
  • R 27 and R 28 preferably independently representing hydrogen, halogen,-CF 3 , -OCF 3 , -OCH 2 CF 3 , -OR 29 , lower alkyl, aryl or aryl-lower alkyl, or together forming a bridge -OCH 2 O-;
  • y is 1 , 2, 3 or 4;
  • R 29 and R 30 independently are hydrogen, -COR 31 , -SO 2 R 31 , lower alkyl, aryl or aryl-lower alkyl;
  • R 31 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 36 and R 39 independently are hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 38 is hydrogen, -OR 40 , -NR 40 R 41 , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SR 40 , -CHF 2 , - OCHF 2 , -OCF 2 CHF 2 , -CONR 40 R 41 , -(CH 2 ) X CONR 40 R 41 , -O(CH 2 ) X CONR 40 R 41 , -(CH 2 ) x OR 40 , -(CH 2 ) X NR 40 R 41 , -OCOR 40 or -CO 2 R 40 ; x is 1 , 2, 3 or 4;
  • R 40 and R 41 independently are hydrogen, -COR 42 , -SO 2 R 42 , lower alkyl, aryl or aryl-lower alkyl;
  • R 42 is hydrogen, lower alkyl, aryl or aryl-lower alkyl.
  • R 1 and R 2 independently are hydrogen or lower alkyl or together form a valence bond
  • R 3 and R 4 independently are hydrogen or lower alkyl
  • n 0, 1 , 2 or 3;
  • n 0 or 1 ;
  • R 5 is hydrogen, lower alkyl, aryl-lower alkyl or -OR 6 ;
  • R 6 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 8 and R 9 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3> -NO 2 , -OR 11 , -NR 11 R 12 , lower alkyl, aryl, -SCF 3 , -SR 11 , -CHF 2) -OCHF 2 , -OSO 2 R 11 , -CONR 1 R 12 , -CH 2 OR 11 , -CH 2 NR 11 R 12 , -OCOR 11 , -CO 2 R 13 or -OSO 2 CF 3> or R 8 and R 9 together form a bridge -OCH 2 O- or - OCH 2 CH 2 O-;
  • R 13 is hydrogen, lower alkyl, aryl-lower alkyl or aryl
  • R 10 is hydrogen, lower alkyl, aryl-lower alkyl or aryl;
  • R 14 and R 15 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -O(CH 2 ),CF 3 , -NO 2 , -OR 16 , -NR 16 R 17 , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SR 16 , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2 , -OSO 2 CF 3 , -CONR 16 R 17 , -(CH 2 ),CONR 16 R 17 , -O(CH 2 ),CONR 16 R 17 , -(CH 2 ),COR 16 , -(CH 2 ),COR 16 , -(CH 2 ),COR 16 , -(CH 2 ),OR 16 , -O(CH 2 ),OR 16 , -(CH 2 ),NR 16 R 17 , -0(CH 2 ),NR 16 R 17 , -
  • R 14 andR 15 preferably independently representing hydrogen, halogen, -CF 3 , -OCF 3 , -OR 16 , -NR 16 R 17 , lower alkyl, aryl, aryl-lower alkyl, -OSO 2 CF 3 , -CONR 6 R 17 , -CH 2 OR 16 , -CH 2 NR 16 R 17 , -OCOR 16 or -CO 2 R 18 ; or together forming a bridge -OCH 2 O-;
  • I is 1 , 2, 3 or 4;
  • R 16 and R 17 independently are hydrogen, -COR 18 , -SO 2 R 18 , lower alkyl, aryl, or R 16 and R 17 together form a cyclic alkyl bridge containing from 2 to 7 carbon atoms;
  • Q is -NR 23 -, -O- or -S-;
  • R 19 , R 20 , R 21 and R 22 independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 24 , -NR 24 R 25 , lower alkyl, aryl, aryl-lower alkyl, SCF 3 , -SR 24 , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2 , -OSO 2 CF 3 , -CONR 24 R 25 , -CH 2 CONR 24 R 25 , -OCH 2 CONR 24 R 25 , -CH 2 OR 24 , -CH 2 NR 24 R 25 , -OCOR 24 or -CO 2 R 24 , or R 19 and R 20 , R 20 and R 21 or R 21 and R 22 together form a bridge -OCH 2 O-;
  • R 24 and R 25 independently are hydrogen, -COR 26 , -SO 2 R 26 , lower alkyl, aryl or aryl-lower alkyl;
  • R 26 is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 3a , R 3 , R 4a and R 4b independently are hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -OCH 2 CF 3 , -NO 2 , -OR 24a , -NR 24a R 25a , lower alkyl, aryl, aryl-lower alkyl, SCF 3 , -SR 24a , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2, -OSO 2 CF 3 , -CONR 24a R 25a , -CH 2 CONR 24a R 25a , -OCH 2 CONR 24a R 25a , -CH 2 OR 24a , -CH 2 NR 24a R 25a , -OCOR 24a or -CO 2 R 24a ; wherein R 24a and R 25a independently are hydrogen, -COR 26a , -SO 2 R 26a , lower alkyl, aryl or ary
  • R 6a is hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 3a and R 3b , R 4a and R 4b or R 3a and R 4b together form a bridge -(CH 2 ) r ;
  • i is 1 , 2, 3 or 4;
  • a, b, c and d independently are 0, 1 , 2, 3 or 4;
  • q 0,1 or 2;
  • R 5a and R 5b independently are hydrogen, lower alkyl, -(CH 2 ) k -OH, -(CH 2 ) k - NR 6a R 6 , aryl or aryl-lower alkyl;
  • k is 2, 3 or 4;
  • R 6a and R 6b independently are hydrogen, lower alkyl or aryl-lower alkyl
  • K preferably representing -(CH 2 )- -N- -O— (CH 2 ) 2 -N— (CH H 2' ⁇
  • r and s independently are 0, 1 or 2;
  • F' is >CR 38 - or >N
  • Q' is -NR 36 -, -O- or -S-;
  • R 27 , R 28 ,R 32 , R 33 , R 34 and R 35 are independently hydrogen, halogen, -CN, -CF 3 , -OCF 3 , -O(CH 2 ) y CF 3 , -NO 2 , -OR 29 , -NR 29 R 30 , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SR 29 , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2 , -OSO 2 R 29 , -OSO 2 CF 3 , -CONR 29 R 30 , -(CH 2 ) y CONR 29 R 30 , -O(CH 2 ) y CONR 29 R 30 , -(CH 2 ) y OR 29 , -(CH 2 ) y NR 9 R 30 , -OCOR 29 or -CO 2 R 29 ;
  • R 27 and R 28 preferably independently representing hydrogen; halogen such as -Cl or -F; -CF 3 ; -OCF 3 . -OCHF 2 ; -OCH 2 CF 3 ; -OR 29 wherein R 29 is hydrogen or lower alkyl; lower alkyl such as methyl, isopropyl or tert-butyl; lower alkylthio; -SCF 3 ; -CH 2 OH; -COO-lower alkyl; aryl or -CONH 2 ; or together forming a bridge -OCH 2 O-;
  • y is 1 , 2, 3 or 4;
  • R 36 and R 39 independently are hydrogen, lower alkyl, aryl or aryl-lower alkyl
  • R 38 is hydrogen, -OR 40 , -NR 40 R 41 , lower alkyl, aryl, aryl-lower alkyl, -SCF 3 , -SR 40 , -CHF 2 , -OCHF 2 , -OCF 2 CHF 2 , -CONR 40 R 41 , -(CH 2 ) X CONR 40 R 41 , -O(CH 2 ) X CONR 40 R 41 , -(CH 2 ) x OR 40 , -(CH 2 ) X NR 40 R 41 , -OCOR 40 or -CO 2 R 40 ; wherein x is 1 , 2, 3 or 4;
  • R 40 and R 41 independently are hydrogen, -COR 42 , -SO 2 R 42 , lower alkyl, aryl or aryl-lower alkyl;
  • R 42 is hydrogen, lower alkyl, aryl or aryl-lower alkyl.
  • Preferred specific compounds represented by the formulae VI and VII are the following:
  • Especially preferred according to the present invention are the following compounds which show a particularly high affinity to the human giucagon receptor:
  • the compounds of the present invention may have one or more asymmetric centres and it is intended that any optical isomers, as separated, pure or partially purified optical isomers or racemic mixtures thereof are included in the scope of the invention.
  • one or more carbon-carbon or carbon-nitrogen double bonds may be present in the compounds which brings about geometric isomers. It is intended that any geometric isomers, as separated, pure or partially purified geometric isomers or mixtures thereof are included in the scope of the invention.
  • the compounds of the present invention may exist in different tautomeric forms, eg the following tautomeric forms:
  • any tautomeric forms which the compounds are able to form are included in the scope of the present invention. Owing to their efficacy in antagonizing the giucagon receptor the present compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases.
  • the present compounds may be applicable for the treatment of hyperglycemia associated with diabetes of any cause or associated with other diseases and conditions, eg impaired glucose tolerance, insulin resistance syndromes, syndrome X, type I diabetes, type II diabetes, hyperlipidemia, dyslipidemia, hypertriglyceridemia, glucagonomas, acute pancreatitis, cardiovascular diseases, cardiac hypertrophy, gastrointestinal disorders, diabetes as a consequence of obesity etc.
  • diseases and conditions eg impaired glucose tolerance, insulin resistance syndromes, syndrome X, type I diabetes, type II diabetes, hyperlipidemia, dyslipidemia, hypertriglyceridemia, glucagonomas, acute pancreatitis, cardiovascular diseases, cardiac hypertrophy, gastrointestinal disorders, diabetes as a consequence of obesity etc.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising, as an active ingredient, at least one compound according to the present invention together with one or more pharmaceutically acceptable carriers or excipients.
  • the present invention relates to a method of lowering blood glucose in a mammal, comprising administering to said mammal an effective amount of a compound according to the invention.
  • the present invention is also concerned with the use of a compound according to the invention for the manufacture of a medicament for treating type I or type II diabetes or hyperglycemia, or for lowering blood glucose in a mammal.
  • Pharmaceutical formulations and administration methods are also concerned with the use of a compound according to the invention for the manufacture of a medicament for treating type I or type II diabetes or hyperglycemia, or for lowering blood glucose in a mammal.
  • the compounds according to the invention may be administered for therapy by any suitable route including oral, rectal, nasal, pul- monal, topical (including buccal and sublingual), transdermal, vaginal and parenteral (including subcutaneous, intramuscular, intravenous and intradermal), the oral route being preferred. It will be appreciated that the preferred route will vary with the condition and age of the recipient, the nature of the condition to be treated, and the chosen active ingredient.
  • a typical dosage is in the range of from 0.05 to about 1000 mg, preferably of from about 0.1 to about 500 mg, such as of from about 0.5 mg to about 250 mg for administration one or more times per day such as 1 to 3 times per day. It should be understood that the exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated as well as other factors evident to those skilled in the art.
  • parenteral routes such as intravenous, intrathecal, intramuscular and similar administration
  • typically doses are on the order of about 1/2 the dose employed for oral administration.
  • the compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof.
  • One example is an acid addition salt of a compound having the utility of a free base.
  • a compound of formula I contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of a free base of formula I with a chemical equivalent of a pharmaceutically acceptable acid, for example, inorganic and organic acids, for example: maleic, fumaric, benzoic, ascorbic, pamoic, succinic, bis- methylene salicylic, methanesulfonic, ethanedisulfonic, acetic, oxalic, propionic, tartaric, sali- cylic, citric, pyruvic, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benz
  • the compounds of the invention may be administered alone or in combination with pharma- ceutically acceptable carriers, in either single or multiple doses.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient. These formulations may be in the form of powder or granules, as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oii liquid emulsion.
  • the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge.
  • the amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g.
  • the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
  • a typical tablet which may be prepared by conventional tabletting techniques may contain:
  • Active compound (as free compound or salt 100 mg thereof)
  • the preparation may contain a compound of formula I dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application.
  • a liquid carrier in particular an aqueous carrier
  • the carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.
  • the pharmaceutical composition of the invention may comprise a compound of formula I combined with one or more other pharmacologically active compounds, e.g. an an- tidiabetic or other pharmacologically active material, including compounds for the treatment and/or prophylaxis of insulin resistance and diseases wherein insulin resistance is the pato- physiological mechanism.
  • Suitable antidiabetics comprise insulin, GLP-1 derivatives such as those disclosed in WO 98/08871 (Novo Nordisk A S) which is incorporated herein by refer- ence as well as orally active hypoglycaemic agents such as sulphonylureas, e.g. glibencla- mide and glipizide; biguanides, e.g.
  • metformin metformin
  • benzoic acid derivatives e.g. repaglinide
  • thiazolidinediones e.g. troglitazone and ciglitazone, as well as PPAR and RXR agonists.
  • Giucagon Binding Assay (I) Binding of compounds to the giucagon receptor was determined in a competition binding assay using the cloned human giucagon receptor.
  • antagonism was determined as the ability of the compounds to inhibit the amount of cAMP formed in the presence of 5 nM giucagon.
  • Plasma membranes were prepared by growing cells to confluence, detaching them from the surface and resuspending the cells in cold buffer (10 mM tris/HCI), pH 7.4 containing 30 mM NaCl, 1 mM dithiothreitol, 5 mg/l leupeptin (Sigma), 5 mg/l pepstatin (Sigma), 100 mg/l baci- tracin (Sigma) and 15 mg/l recombinant aprotinin (Novo Nordisk)), homogenization by two 10-s bursts using a Polytron PT 10-35 homogenizer (Kinematica), and centrifugation upon a layer of 41 w/v% sucrose at 95.000 * g for 75 min. The white band located between the two layers was diluted in buffer and centrifuged at 40.000 * g for 45 min. The precipitate containing the plasma membranes was suspended in buffer and stored at -80°C until required.
  • Giucagon was iodinated according to the chloramine T method (Hunter and Greenwood, Na- ture 194, 495 (1962)) and purified using anion exchange chromatography (J ⁇ rgensen et al, Hormone and Metab. Res. 4, 223-224 (1972). The specific activity was 460 ⁇ Ci/ ⁇ g on day of iodination. Tracer was stored at -18°C in aliquots and were used immediately after thawing.
  • Binding assays were carried out in triplicate in filter microtiter plates (MADV N65, Millipore).
  • the buffer used in this assay was 25 mM HEPES pH 7.4 containing 0.1% human serum albumin (Sigma, grade V).
  • Giucagon was dissolved in 0.05 M HCI, added equal amounts(w/w) of HSA and freeze-dried. On the day of use, it was dissolved in water and diluted in buffer to the desired concentrations. 175 ⁇ l of sample (giucagon or test compounds) was added to each well. Tracer (50.000 cpm) was diluted in buffer and 15 ⁇ l was added to each well. 0.5 ⁇ g freshly thawed plasma membrane protein diluted in buffer was then added in 15 ⁇ l to each well.
  • the functional assay was carried out in 96 well microtiter plates (tissue culture plates, Nunc).
  • the resulting buffer concentrations in the assay were 50 mM tris/HCI, 1 mM EGTA, 1.5 mM MgSO 4 , 1.7 mM ATP, 20 ⁇ M GTP, 2 mM IBMX, 0.02% tween-20 and 0.1% HSA.
  • pH was 7.4 Giucagon and proposed antagonist were added in 35 ⁇ l diluted in 50 mM tris/HCI, 1 mM EGTA, 1.85 mM MgSO 4 , 0.0222 % tween-20 and 0.111 % HSA, pH 7.4.
  • the total assay volume was 140 ⁇ l.
  • the assay was incubated for 2 hours at 37°C with continuous shaking. Reaction was terminated by addition of 25 ⁇ l 0.5 N HCI.
  • cAMP was measured by the use of a scintillation proximity kit (Amersham).
  • Giucagon Binding Assay (lh Receptor binding was assayed using the cloned human receptor (Lok et al, Gene 140, 203- 209 (1994)). The receptor inserted in the pLJ6' expression vector using EcoRI/SSt1 restriction sites (Lok et al) was expressed in a baby hamster kidney cell line (A3 BHK 570-25). Clones were selected in the presence of 0.5 mg/ml G-418 and were shown to be stable for more than 40 passages. The Kd was shown to be 0.1 nM.
  • Plasma membranes were prepared by growing cells to confluence, detaching them from the surface and resuspending the cells in cold buffer (10 mM tris/HCI), pH 7.4 containing 30 mM NaCl, 1 mM dithiothreitol, 5 mg/l leupeptin Sigma), 5 mg/l pepstatin (Sigma), 100 mg/l baci- tracin (Sigma) and 15 mg/l recombinant aprotinin (Novo Nordisk)), homogenization by two 10-s bursts using a Polytron PT 10-35 homogenizer (Kinematica), and centrifugation. The ho- mogenate was resuspended and centrifuged again. The final precipitate containing the plasma membranes was suspended in buffer and stored at -80 C C until required.
  • cold buffer 10 mM tris/HCI
  • pH 7.4 containing 30 mM NaCl, 1 mM dithiothreitol, 5 mg/l le
  • Binding assays were carried out in duplicate in polypropylene tubes or microtiter plates.
  • the buffer used in this assay was 25 mM HEPES pH 7.4 containing 0.1 % bovine serum albumin
  • the functional assay determined the ability of the compounds to antagonize glucagon- stimulated formation of cAMP in a whole-cell assay.
  • the assay was carried out in borosilicate glass 12 x 75 tubes.
  • the buffer concentrations in the assay were 10 mM HEPES, 1 mM EGTA, 1.4 mM MgCI 2t 0.1 mM IBMX, 30 mM NaCl, 4.7 mM KCI, 2.5 mM NaH 2 PO 4 , 3mM glucose and 0.2% BSA.
  • the pH was 7.4. Loose whole cells (0.5 ml, 10 6 /ml) were pretreated with various concentrations of compounds for 10 min at 37°C, then challenged with giucagon for 20 min.
  • the compounds of general formula I may be prepared according to one embodiment of the invention, the alkylidene hydrazides of general formula II, as indicated in Scheme I, that is, by converting an ester of a carboxylic acid, for example, an aromatic acid to a hydrazide derivative and further reacting that product compound with a substituted aldehyde or ketone to yield a substituted alkylidene hydrazide.
  • HN-N r— (CH 2 ) n — B-(K)— D
  • A, B, K, D, m, n and R 4 are as defined for formula I and R a is lower alkyl.
  • the reactions are performed between 0°C to 130°C, preferably between 20°C to 100°C, most preferably at or about the reflux temperature of the solvent.
  • the reactions are preferably con- ducted under an inert atmosphere such as N 2 or Ar.
  • the solvent may be removed by concentration at atmospheric or reduced pressure.
  • the product can be further purified by either recrystallization from a solvent such as ethyl alcohol, methyl alcohol, isopropyl alcohol, toluene, xylene, hexane, tetrahydrofuran, diethyl ether, dibutyl ether, water or a mixture of two or more of the above.
  • the product can be purified by column chromatography using dichloromethane/methanol or chloroform/methanol or isopropyl alcohol as eluent.
  • the corresponding fractions are concentrated either at atmospheric pressure or in vacuo to provide the pure aroyl hydrazide.
  • aromatic acid hydrazides The methyl or ethyl ester of the corresponding aromatic acid, such as for example a substituted benzoic acid ester, is dissolved in ethanol and hydrazine (5 eq) is added. The reaction is refluxed overnight under nitrogen. Upon cooling the substituted hydrazide derivative usually precipitates. After filtration the product is usually recrystallized from hot methanol, ethanol or isopropyl alcohol. In cases where the hydrazide does not precipitate, the reaction is concen- trated under vacuo and chromatographed over silica gel using dichloromethane/methanol as the eluent. Specific examples illustrating the preparation of aromatic hydrazides are provided below.
  • step D Preparation of 2.3-Dichloro-4-hydroxybenzoic acid hydrazide and 2.5-dichloro-4- hydroxybenzoic acid hydrazide
  • 2,5-dichloro-4-hydroxybenzoic acid hydrazide was prepared in a similar way starting from 2,5-dichloro-4-hydroxybenzoate.
  • the product was purified via silica gel column chromatography using CH2Cl2/MeOH ( 95/5 to 80/20) to afford the title compound.
  • Methyl-4-hydroxybenzoate (35.5 g, 0.233 mol) was dissolved in 200 mL of warm (65 °C) acetic acid. A solution of iodine monochloride (37.8 g, 0.233 mol) in 50 mL of acetic acid was added slowly (40 minutes) to the methyl-4-hydroxybenzoate solution, while maintaining a temperature of 65 °C and vigorous stirring. The product crystallizes from solution upon cooling to room temperature and standing overnight. The crystals were collected on a filter, washed with water, then dried under vacuum. Methyl-4-hydroxy-3-iodobenzoate was obtained as white crystals (28.6 g, 44%).
  • Methyl-4-hydroxy-3-iodobenzoate (2.00 g, 7.2 mmol) was dissolved into 5 mL of dry DMF. Copper(l) cyanide (0.72 g, 8.0 mmol) and a small crystal of sodium cyanide was added. The mixture was flushed with nitrogen, placed in an oil heating bath (100-110 °C), and stirred overnight. TLC indicated nearly complete reaction. The mixture was cooled and the solids removed by filtration. The solids were extracted with DMF (3 mL). The filtrate and washings were taken up in 100 mL of ethyl acetate, then washed with 3 portions of saturated sodium chloride solution.
  • Methyl-3-cyano-4-hydroxybenzoate (2.71 g, 15.3 mmol) was dissolved in 50 mL of THF. The solution was chilled in an ice bath, and 2.0M potassium hydroxide (17 mL, 34 mmol) was added dropwise. The resulting mixture was stirred at room temperature overnight. TLC indicated complete reaction. The THF was removed by rotary evaporation. The aqueous re- sidue was acidified with aqueous trifluoroacetic acid and purified by reverse-phase HPLC (C- 18, 0.1 % TFA in water and acetonitrile). 3-Cyano-4-hydroxybenzoic acid was obtained as a white powder (2.1g, 84%) after lyophilization.
  • Step E The Boc-hydrazide (1.8g, 6.5 mmol) was suspended in 50 mL of chloroform and cooled in an ice-bath. Trifluoroacetic acid was added with stirring, and the resulting solution stood for 4 hours at 0 °C. TLC indicated complete reaction. Solvent and excess TFA were removed by rotary evaporation. The remaining oil was purified by reverse-phase liquid chromatography (Aquasil C-18 column, water/acetonitrile/0.1 % TFA). The title compound was obtained as a white solid (0.24 g, 13%).
  • Step A Silver nitrate (17 g, 0.1 mol) was dissolved in water (10 mL) and treated with 1 N NaOH (300 mL, 0.3 mol). The brown precipitate which was formed was stirred for 30 minutes and the supernatant was decanted. The brown silver oxide was washed with additional volumes of water (3x). To the silver oxide above was added 1N NaOH (150 mL) and 4-hydroxynaphthaldehyde (1 g, 6 mmol)). The mixture was heated to 70 °C for 10 minutes after which additional amounts of 4-hydroxynaphthaldehyde (5.5 g, 32 mmol) was added in portions. The mixture was kept at 80 °C for 16 hours. TLC analysis indicated incomplete conversion.
  • Lx is a leaving group such as -Cl, -Br, -I, -OSO 2 CH 3 , -OSO 2 p-tolyl or -OSO 2 CF 3 ;
  • an ether-substituted aryl-aldehyde can be prepared by stirring hy- droxybenzaldehydes or hydroxynaphthaldehydes in an organic solvent such as acetone, meth- ylethyl ketone, dimethylformamide, dioxane, tetrahydrofuran, toluene, ethylene glycol dimethyl ether, sulfolane, diethylether, water or a compatible mixture of two or more of the above solvents with an equimolar amount of an alkyl halide or an aryl-lower alkyl halide and in the pres- ence of 1 to 15 equivalents (preferably 1 to 5 equivalents) of a base such as sodium hydride, potassium hydride, sodium or potassium methoxide, ethoxide or tej -butoxide, sodium, potassium or cesium carbonate, potassium or cesium fluoride, sodium or potassium hydroxide or organic bases
  • the reaction can be performed at 0°C to 150°C, preferably at 20°C to 100°C and preferably in an inert atmosphere of N 2 or Ar.
  • the reaction is complete the mixture is filtered, concentrated in vacuo and the resulting product optionally purified by column chromatography on silica gel using ethyl acetate/hexane as eluent.
  • the compound can also (when appropriate) be purified by recrystallization from a suitable solvent such as ethyl alcohol, ethyl acetate, isopropyl alcohol, water, hexane, toluene or their compatible mixture. Specific examples illustrating the preparation of ether-substituted aryl-aldehydes are provided below.
  • the crude syrup was heated neat in an oil bath at 200 °C for 6 h.
  • the crude material was dissolved in chloroform and filtered through a pack of silica gel.
  • the crude product (yield 72%) was used as is in the next step for O-alkylation.
  • a small portion was purified using prep-TLC to give a pure sample of 3-allyl-4-hydroxy-5-methoxy-benzaldehyde.
  • step D This type of aldehydes can be coupled to hydrazides using the methodology as described in step D to give a compound of formula IXa.
  • these compounds can undergo rearrangement by treatment with base as described below (step C), followed by coupling to a hydrazide (step D) to give a compound of formula IXb.
  • the resulting carbonyl compounds are treated with the corresponding acylhydrazide in a solvent.
  • the solvent may be one of the following: ethyl alcohol, methyl alcohol, isopropyl alcohol, tert-butyl alcohol, dioxane, tetrahydrofuran, toluene, chlorobenzene, anisole, benzene, chloroform, dichloromethane, DMSO, acetic acid, water or a compatible mixture of two or more of the above solvents.
  • a catalyst such as acetic acid can be added.
  • a dehydrating reagent such as triethylorthoformate can also be added to the reaction mixture.
  • the reaction is performed by stirring the reaction mixture preferably under an inert atmosphere of N 2 or Ar at temperatures between 0°C to 140°C, preferably between 10°C to 80°C.
  • the product simply crystallizes out when the reaction is completed and is isolated by suction filtration. It can be further recrystallized if necessary from a solvent such as the above described reaction sol- vents.
  • the product can also be isolated by concentration of the reaction mixture in vacuo, followed by column chromatography on silica gel using a solvent system such as chloroform/methanol or dichloromethane/methanol or chloroform/ethyl acetate to give a compound of formula IXb.
  • the product simply crystallizes out when the reaction is completed and is isolated by suction filtration. It can be further recrystal- lized if necessary from a solvent such as the above described reaction solvents.
  • the product can also be isolated by concentration of the reaction mixture in vacuo. followed by column chromatography on silica gel using a solvent system such as chloroform/-methanol or dichloromethane/methanol or chloroform/ethyl acetate. The product is isolated by concentration in vacuo of the appropriate fractions. Specific examples illustrating the preparation of compounds according to the invention are provided below. EXAMPLE 6:

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des composés non peptidiques comprenant un motif hydrazide central ainsi que leurs procédés de synthèse. Les composés ont un effet antagoniste sur l'action de l'hormone peptidique glucagon.
EP98929244A 1997-07-01 1998-07-01 Antagonistes/agonistes inverses du glucagon Withdrawn EP0994848A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88678597A 1997-07-01 1997-07-01
US886785 1997-07-01
US3251698A 1998-02-27 1998-02-27
US32516 1998-02-27
PCT/DK1998/000287 WO1999001423A1 (fr) 1997-07-01 1998-06-30 Antagonistes/agonistes inverses du glucagon

Publications (1)

Publication Number Publication Date
EP0994848A1 true EP0994848A1 (fr) 2000-04-26

Family

ID=26708528

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98929244A Withdrawn EP0994848A1 (fr) 1997-07-01 1998-07-01 Antagonistes/agonistes inverses du glucagon

Country Status (11)

Country Link
EP (1) EP0994848A1 (fr)
JP (1) JP2003514508A (fr)
KR (1) KR20010020590A (fr)
CN (1) CN1267281A (fr)
AU (1) AU749271B2 (fr)
BR (1) BR9810378A (fr)
HU (1) HUP0002373A3 (fr)
IL (1) IL133377A0 (fr)
NO (1) NO996550L (fr)
PL (1) PL337781A1 (fr)
WO (1) WO1999001423A1 (fr)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6927214B1 (en) 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
WO2000042026A1 (fr) * 1999-01-15 2000-07-20 Novo Nordisk A/S Agonistes non peptidiques de glp-1
EP1183229B1 (fr) * 1999-05-17 2005-10-26 Novo Nordisk A/S Antagonistes/agonistes inverses de glucagon
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
AUPQ262499A0 (en) 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
ES2433476T3 (es) 2000-01-21 2013-12-11 Novartis Ag Combinaciones que contienen inhibidores de la dipeptidilpeptidasa-IV y agentes 5 antidiabéticos
WO2001055107A2 (fr) * 2000-01-28 2001-08-02 Melacure Therapeutics Ab Nouveaux amines et amides aromatiques agissant sur les recepteurs de la melanocortine
CA2411552A1 (fr) * 2000-06-23 2002-01-03 Novo Nordisk A/S Antagonistes/agonistes inverses du glucagon
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
WO2002040444A1 (fr) * 2000-11-17 2002-05-23 Novo Nordisk A/S Antagonistes/agonistes inverses de glucagon
JP2004513936A (ja) * 2000-11-17 2004-05-13 ノボ　ノルディスク　アクティーゼルスカブ グルカゴンアンタゴニスト／逆アゴニスト
AU2002223500A1 (en) 2000-11-17 2002-05-27 Novo-Nordisk A/S Glucagon antagonists/inverse agonists
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
EP2243776A1 (fr) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Piperidines substituées et leur utilisation dans le traitement de maladies liées au recepteur histaminique H3
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
JP2005518391A (ja) 2001-12-21 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ Ｇｋ活性化剤としてのアミド誘導体
WO2003064404A1 (fr) 2002-02-01 2003-08-07 Dainippon Pharmaceutical Co., Ltd. Hydrazides d'acide 2-furancarboxylique et compositions pharmaceutiques les contenant
AUPS120902A0 (en) * 2002-03-19 2002-04-18 Unisearch Limited Iron chelators as anti-proliferative agents against tumour cells
EP1506777A4 (fr) * 2002-05-22 2007-07-18 Sanwa Kagaku Kenkyusho Co Medicament contre l'obesite a base de methylidene hydrazide
MXPA05000130A (es) 2002-06-27 2005-02-17 Novo Nordisk As Derivados de aril-carbonilo como agentes terapeuticos.
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
US7078419B2 (en) 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
JP4629657B2 (ja) 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
JP2005060385A (ja) * 2003-07-31 2005-03-10 Dainippon Pharmaceut Co Ltd ２−フランカルボン酸ヒドラジド化合物からなる医薬
EP1670815A2 (fr) 2003-09-30 2006-06-21 Novo Nordisk A/S Nouveaux agonistes du recepteur de la melanocortine
ATE498404T1 (de) 2003-12-09 2011-03-15 Novo Nordisk As Regulierung der nahrungspräferenz mit glp-1- agonisten
WO2005066145A1 (fr) 2004-01-06 2005-07-21 Novo Nordisk A/S Heteroaryl-urees et leur utilisation en tant qu'activateurs de glucokinase
WO2005120492A1 (fr) 2004-06-11 2005-12-22 Novo Nordisk A/S Remede contre l'obesite induite par les medicaments au moyen d'agonistes glp-1
DE102004030987A1 (de) * 2004-06-26 2006-01-12 Merck Patent Gmbh Ortho-substituierte (3-Hydroxyphenyl)-essigsäure-benzyliden-hydrazide
EP1841749A1 (fr) 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Derives d'inhibiteurs de thiazole et de thiadiazoles de tyrosine phosphatases
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
CN101137631A (zh) 2004-12-03 2008-03-05 转化技术制药公司 杂芳族葡糖激酶激活剂
EP1853266B1 (fr) 2005-01-10 2011-10-12 Cortendo AB (publ) 2s,4r ketoconazole pour le traitement du diabete, du syndrome metabolique et d'autres conditions
EP2292653B1 (fr) 2005-02-02 2014-05-21 Novo Nordisk A/S Nouveaux dérivés d'insuline
US8067362B2 (en) 2005-02-02 2011-11-29 Novo Nordisk As Insulin derivatives
WO2006102067A1 (fr) 2005-03-21 2006-09-28 Merck & Co., Inc. Derives d'aryle et d'heteroaryle substitues
AU2006229904A1 (en) 2005-03-30 2006-10-05 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
RU2412935C2 (ru) 2005-06-30 2011-02-27 Хай Пойнт Фармасьютикалс, ЛЛС Феноксиуксусные кислоты в качестве активаторов дельта рецепторов ppar
CA2614116A1 (fr) 2005-07-04 2007-01-11 Novo Nordisk A/S Medicaments
CN101263131B (zh) 2005-07-14 2013-04-24 特兰斯特克药品公司 脲葡糖激酶活化剂
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
PL1931350T5 (pl) 2005-09-14 2021-11-15 Takeda Pharmaceutical Company Limited Podanie inhibitorów dipeptydylo-peptydazy
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
EP1801098A1 (fr) 2005-12-16 2007-06-27 Merck Sante Dérivés de 2-Adamantylurea comme inhibiteurs de 11B-HSD1
EP2386540A1 (fr) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Nouveaux composés, leur utilisation et préparation
US7989472B2 (en) 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007110364A1 (fr) 2006-03-28 2007-10-04 High Point Pharmaceuticals, Llc Benzothiazoles presentant une activité sur le récepteur h3 de l'histamine
CA2650619A1 (fr) 2006-05-16 2007-11-29 Merck And Co., Inc. Composes antagonistes du recepteur du glucagon, compositions contenant ces composes, et procedes d'utilisation
CN102295606A (zh) 2006-05-29 2011-12-28 高点制药有限责任公司 合成3-（1，3-苯并间二氧杂环戊烯-5-基）-6-（4-环丙基哌嗪-1-基）-哒嗪的方法及其适用的中间体
CA2664800A1 (fr) 2006-10-02 2008-04-10 Timothy Andrew Stewart Enantiomere de cetoconazole chez les etres humains
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2086951B1 (fr) 2006-11-15 2011-12-21 High Point Pharmaceuticals, LLC Nouvelles 2-(2-hydroxyphényl) benzothiadiazines utilisées pour traiter l'obésité et le diabète
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
EP1935420A1 (fr) 2006-12-21 2008-06-25 Merck Sante Dérivés du 2-adamantyl-butyramide en tant qu'inhibiteurs selectifs de la 11beta-HSD1
WO2008084044A1 (fr) 2007-01-11 2008-07-17 Novo Nordisk A/S Activateurs de l'urée glucokinase
EP2107908A4 (fr) * 2007-02-02 2011-07-20 Redpoint Bio Corp Utilisation d'un inhibiteur de trpm5 pour réguler une sécrétion d'insuline et de glp-1
EP2110374A1 (fr) 2008-04-18 2009-10-21 Merck Sante Dérivés de benzofurane, benzothiophène, benzothiazol en tant que modulateurs FXR
FR2932482B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2932481B1 (fr) 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
US20100035932A1 (en) * 2008-08-07 2010-02-11 Schepetkin Igor A Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
JP5514831B2 (ja) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療のための置換二環式アミン
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
CA2768577A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composes d?oxazepine benzofusionnes en tant qu?inhibiteurs de la coenzyme-stearoyle a delta-9 desaturase
WO2011011506A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
WO2011019538A1 (fr) 2009-08-13 2011-02-17 Merck Sharp & Dohme Corp. Composés cyclopropyle substitués, compositions contenant de tels composés et procédés de traitement
CA2771352A1 (fr) 2009-09-02 2011-03-10 Merck Sharp & Dohme Corp. Aminotetrahydropanes utilises comme inhibiteurs de la dipeptyl peptidase-iv pour traiter ou prevenir le diabete
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
WO2011058193A1 (fr) 2009-11-16 2011-05-19 Mellitech Dérivés de [1,5]-diazocine
FR2953836B1 (fr) 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
WO2011079778A1 (fr) 2009-12-30 2011-07-07 China Shanghai Fochon Pharmaceutical Co Ltd Dérivés de 3-(3-aminopipéridin-1-yl)-5-oxo-1,2,4-triazine à titre d'inhibiteurs de dipeptidyl peptidase iv (dpp-iv)
PT2531501E (pt) 2010-02-03 2014-02-17 Takeda Pharmaceutical Inibidores da cinase de regulação do sinal de apoptose 1
EP2538783B1 (fr) 2010-02-22 2016-06-01 Merck Sharp & Dohme Corp. Aminotétrahydrothiopyranes substitués et dérivés de ceux-ci utilisés en tant qu'inhibiteurs de la dipeptidylpeptidase-iv dans le cadre du traitement du diabète
US20130012432A1 (en) 2010-02-26 2013-01-10 Novo Nordisk A/S Peptides for Treatment of Obesity
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
JP6054861B2 (ja) 2010-03-26 2016-12-27 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
WO2011146358A1 (fr) 2010-05-21 2011-11-24 Merck Sharp & Dohme Corp. Composés hétérocycliques substitués à sept chaînons en tant qu'inhibiteurs de la dipeptidyl-peptidase iv pour le traitement du diabète
WO2012024183A1 (fr) 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Composés spiroxazolidinone
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
MX2013006768A (es) 2010-12-23 2013-07-22 Pfizer Moduladores de receptor de glucagon.
DK2673260T3 (en) 2011-02-08 2016-10-10 Pfizer Glucagonreceptormodulator
BR112013024076A2 (pt) 2011-03-28 2016-12-06 Novo Nordisk As análogos de glucagon
WO2012138845A1 (fr) 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Composés à cyclopropyle substitué, compositions contenant de tels composés et méthodes de traitement
US20140088124A1 (en) 2011-06-02 2014-03-27 Robert J. DeVita Imidazole derivatives
EP2720544B1 (fr) 2011-06-16 2016-12-21 Merck Sharp & Dohme Corp. Composés cyclopropylés substitués, compositions contenant de tels composés et procédés de traitement
EP2734503B1 (fr) 2011-07-22 2015-09-16 Pfizer Inc. Modulateurs des récepteurs de quinolinylglucagon
TWI596110B (zh) 2011-09-23 2017-08-21 諾佛 儂迪克股份有限公司 新穎升糖素類似物
WO2013048916A1 (fr) 2011-09-30 2013-04-04 Merck Sharp & Dohme Corp. Composés de cyclopropyle substitués, compositions contenant ces composés et méthodes de traitement
WO2013062838A1 (fr) 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Composés de pipéridinyle substitués utilisés comme agonistes du récepteur gpr119
WO2013068328A1 (fr) 2011-11-07 2013-05-16 Intervet International B.V. Composés d'acide bicyclo[2.2.2]octan-1-ylcarboxylique comme inhibiteurs de la dgat-1
WO2013068439A1 (fr) 2011-11-09 2013-05-16 Intervet International B.V. Composés 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazépine comme inhibiteurs de dgat1
US9029403B2 (en) 2011-11-10 2015-05-12 Memorial Sloan-Kettering Cancer Center Treatment of ovarian cancer with benzylidenebenzohydrazides
CA2855009C (fr) 2011-11-15 2019-07-09 Merck Sharp & Dohme Corp. Composes de cyclopropyle substitues utiles a titre d'agonistes de gpr119
EP2606894A1 (fr) 2011-12-20 2013-06-26 Sanofi Nouvelle utilisation thérapeutique des antagonistes du récepteur p75
EP2814485A4 (fr) 2012-02-17 2015-08-26 Merck Sharp & Dohme Inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prévention du diabète
MX2014012465A (es) 2012-04-16 2015-01-12 Kaneq Pharma Inc Derivados de fosfonato aromaticos fusionados como precursores de inhibidores de tirosina fosfatasa de proteina 1b.
US9315508B2 (en) 2012-07-23 2016-04-19 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-IV inhibitors
US9867869B2 (en) 2012-12-12 2018-01-16 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
AU2014255608B2 (en) 2013-04-18 2018-01-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
EP3065736B1 (fr) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Composés antagonistes du récepteur du glucagon, compositions correspodantes et méthodes d'utilisation
US10065945B2 (en) 2014-01-24 2018-09-04 Merck Sharp & Dohme Corp. Isoquinoline derivatives as MGAT2 inhibitors
CA2945681A1 (fr) 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Complexe de tannate de sitagliptine
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
AU2015335828B2 (en) 2014-10-24 2018-08-23 Merck Sharp & Dohme Llc Co-agonists of the glucagon and GLP-1 receptors
EP3233799B1 (fr) 2014-12-19 2021-05-19 The Broad Institute, Inc. Ligands du récepteur d2 de la dopamine
EP3233077A4 (fr) 2014-12-19 2018-08-08 The Broad Institute Inc. Ligands des récepteurs dopaminergiques d2
CN104610157A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一类环丙基酰肼和卤代苯类结构的gpr119激动剂及其用途
CN104610156A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一种环丙基酰肼和腈基苯类gpr119激动剂、制备方法及其用途
CN104557717A (zh) * 2015-02-13 2015-04-29 佛山市赛维斯医药科技有限公司 酰肼类gpr119激动剂、制备方法及其用途
CN104610151A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 含酰肼和烷氧苯类结构的化合物、其制备方法及用途
CN104610150A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 含酰肼和腈基苯类结构的化合物、其制备方法及用途
CN104592120A (zh) * 2015-02-13 2015-05-06 佛山市赛维斯医药科技有限公司 一种环丙基酰肼和甲氧苯类gpr119激动剂、制备方法及其用途
CN104592121A (zh) * 2015-02-13 2015-05-06 佛山市赛维斯医药科技有限公司 含酰肼和硝基苯类结构的化合物、其制备方法及用途
CN104672144A (zh) * 2015-02-13 2015-06-03 佛山市赛维斯医药科技有限公司 一种环丙基酰肼和硝基苯类gpr119激动剂、制备方法及其用途
US10800826B2 (en) 2015-10-05 2020-10-13 Merck Sharp & Dohme Corp. Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
CN107151220B (zh) * 2015-10-19 2021-07-20 中国医学科学院药物研究所 含苄氧基苯基的酚类化合物、其制备方法及用途
WO2018034918A1 (fr) 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Composés utiles pour modifier les taux d'acides biliaires pour le traitement du diabète et de maladies cardiométaboliques.
US10414775B2 (en) 2016-08-15 2019-09-17 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
MA49883A (fr) 2017-03-15 2021-04-21 Novo Nordisk As Composés bicycliques aptes à se lier au récepteur de mélanocortine 4
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
WO2020053414A1 (fr) 2018-09-14 2020-03-19 Novo Nordisk A/S Composés bicycliques aptes à se lier aux agonistes du récepteur de la mélanocortine 4
EP3863634A1 (fr) 2018-10-12 2021-08-18 Strongbridge Dublin Limited Lévokétoconazole pour le traitement de l'hyperplasie surrénale congénitale et de l'aldostéronisme primaire
WO2020205688A1 (fr) 2019-04-04 2020-10-08 Merck Sharp & Dohme Corp. Inhibiteurs d'histone désacétylase -3 utiles pour le traitement du cancer, de l'inflammation, de maladies neurodégénératives et du diabète
CN110229056B (zh) * 2019-06-21 2022-11-08 天津科技大学 一种新型姜黄素类似物及其制备方法和应用
EP3842061A1 (fr) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Co-agonistes triazoles agrafés des récepteurs du glucagon et du glp-1
EP3842449A1 (fr) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Co-agonistes d'oléfine agrafés du glucagon et récepteurs glp-1
EP3842060A1 (fr) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Co-agonistes lactames agrafés des récepteurs du glucagon et du glp-1

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859281A (en) * 1971-07-01 1975-01-07 American Home Prod 2,6-dichlorobenzylidenehydrazides
US3746703A (en) * 1971-07-01 1973-07-17 American Home Prod 2,6-dichlorobenzylidenehydrazides
US3836580A (en) * 1971-07-01 1974-09-17 American Home Prod 2,6-dichlorobenzylidenehydrazides
US4334015A (en) * 1979-05-23 1982-06-08 Minnesota Mining And Manufacturing Company Imaging compositions
DE4033808A1 (de) * 1990-04-11 1991-10-17 Bayer Ag Naphthalinderivate
JPH04121717A (ja) * 1990-09-12 1992-04-22 Fuji Photo Film Co Ltd 新規な有機非線形光学材料及びそれを用いた光波長の変換方法
JP3529491B2 (ja) * 1995-05-16 2004-05-24 旭電化工業株式会社 感熱記録材料
JPH11514651A (ja) * 1995-10-31 1999-12-14 メルク エンド カンパニー インコーポレーテッド 置換ピリジルピロール、前記化合物を含む組成物及び使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9901423A1 *

Also Published As

Publication number Publication date
CN1267281A (zh) 2000-09-20
HUP0002373A2 (hu) 2000-10-28
WO1999001423A1 (fr) 1999-01-14
IL133377A0 (en) 2001-04-30
BR9810378A (pt) 2000-08-29
PL337781A1 (en) 2000-09-11
JP2003514508A (ja) 2003-04-15
NO996550D0 (no) 1999-12-29
HUP0002373A3 (en) 2000-11-28
NO996550L (no) 2000-02-29
AU7908398A (en) 1999-01-25
WO1999001423A8 (fr) 1999-05-14
KR20010020590A (ko) 2001-03-15
AU749271B2 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
EP0994848A1 (fr) Antagonistes/agonistes inverses du glucagon
US6613942B1 (en) Glucagon antagonists/inverse agonists
RU2280025C2 (ru) Новые производные аминодикарбоновых кислот, обладающие фармацевтическими свойствами
EP1663979B1 (fr) Composes de phenyle ou de pyridyle amide utiles comme antagonistes de la prostaglandine e2
JP2005505618A (ja) ｐ３８キナーゼ阻害剤としてのビフェニル誘導体
US20040082798A1 (en) Novel amino dicarboxylic acid derivatives with pharmaceutical properties
MXPA05006701A (es) Moduladores de asma y de inflacion alergica.
AU2002253010A1 (en) Acylated indanyl amines and their use as pharmaceuticals
JPH09511529A (ja) 芳香族化合物
WO2002064545A1 (fr) Amines indanyle acyles et leurs utilisation comme agents pharmaceutiques
WO2003004458A1 (fr) Composes nouveaux
ZA200201138B (en) Novel dicarboxylic acid derivatives with pharmaceutical properties.
KR20040082425A (ko) Ｐ38 억제제로 유용한 니코틴아미드 유도체
ZA200600819B (en) Cycloalkylidene compounds as modulators of estrogen receptor
SK12892001A3 (sk) Zlúčeniny a prostriedky ako inhibítory proteázy
WO2007062145A2 (fr) Composes chimiques
JP2006504767A (ja) フェニル化合物
JP2008503588A (ja) 化学化合物
EP1113000A1 (fr) Derives de benzene et leur utilisation medicale
US7345075B2 (en) 1,2 diarylbenzimidazoles and their pharmaceutical use
JP2000001431A (ja) 尿酸排泄剤
JP2001139575A (ja) 新規ピラゾロピリジン誘導体
TWI396543B (zh) 取代丙烯醯胺衍生物及含有它之醫藥組成物
JPH033658B2 (fr)
WO1998057935A1 (fr) Derives d'acide 2-sulfamoylbenzoique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 20000201;RO PAYMENT 20000201;SI PAYMENT 20000201

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KUKI, ATSUO

Inventor name: KIEL, DAN

Inventor name: HONG, YUFENG

Inventor name: GREGOR, VLAD

Inventor name: LING, ANTHONY

Inventor name: TENG, MIN

Inventor name: SAMS, CHRISTIAN

Inventor name: GONZALES, JAVIER

17Q First examination report despatched

Effective date: 20010514

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030903